Ashkan Abbey, MD

Ashkan Abbey, MD, reviews findings from the DAVIO2 and VERONA clinical trials for the bioerodible intravitreal insert.

A panelist discusses how careful timing, patient education, and bilateral treatment planning strengthen real-world NT-501 management for MacTel type 2.

A panelist discusses how successful NT-501 integration in MacTel care requires both strategic eye selection and overcoming financial and institutional barriers.

A panelist discusses how individualized imaging-based decisions guide when to initiate NT-501 therapy in both early and advanced stages of MacTel type 2.

A panelist discusses how strategic eye selection and proactive patient counseling optimize success and satisfaction with NT-501 implantation for bilateral MacTel type 2.

A panelist discusses how evolving imaging and the approval of NT-501 therapy are transforming macular telangiectasia type 2 from a diagnostic challenge into a treatable condition.

Data suggests the candidate can reduce the number of injections and treatment burden for patients

Ashkan Abbey, MD, shares insights from the one-year data for the phase 2 DAVIO2 trial and the impact of tyrosine kinase inhibitors on reducing treatment burden.